MENU
KROS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Keros Therapeutics (KROS) Ownership - Who owns Keros Therapeutics?
Profile
Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
136
Web
https://www.kerostx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
786.65M
P/E Ratio
N/A
Total Cash
530.68M
Projected Growth
N/A
Total Debt
19.29M
Revenue
651K
Risk (Beta)
1.14
Dividend Yield
N/A
Total Cash/Share
13.10
Total Debt/Equity
N/A
Revenue/Share
0.02 USD as % of share price
Fundamentals
KROS
Capitalization
787M
P/E Ratio
N/A
Risk (Beta)
1.14
Dividend Yield
N/A
Total Cash
531M
Total Cash/Share
13.10
Total Debt
19.3M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.02%
Revenue
651K
ROE
N/A
Book Value
533M
P/B Ratio
1.37
Cash Flow
N/A
Earnings
-5.22
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
4K
Current Ratio
19.03
Current Revenue Per Employee
2425.00
Dividends Per Share - Security
N/A
EBITDA
-185.94M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-40.10
Shares Held By Institutions
2.74B
Shares Outstanding - Current
40.5M
Total Liabilities
46.4M
Total Volume MTD
N/A
Value
-1
Gain YTD
-54.728
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
1050 Waltham Street
Phone
+1 617 314-6297
Employees
136
Web
https://www.kerostx.com